NervGen Pharma To Present On Its Drug Candidate NVG-291 And Spinal Cord Injury At The H.C. Wainwright 25th Annual Global Investment Conference
VANCOUVER, BC. — NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that President… Read More




